Skip to Main content Skip to Navigation
Journal articles

Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.

Abstract : The advent of anti-Tumor Necrosis Factor (TNF) therapy has changed the way of treating inflammatory bowel disease (IBD). However, primary and secondary failure are relatively frequent with all anti-TNF agents, which are available only as parenteral agents. Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors. It first proved its efficacy as an immunosuppressive regimen after renal transplantation, and was recently approved by the FDA for rheumatoid arthritis. First data in IBD are promising, especially in ulcerative colitis. Ongoing clinical trials in both UC and Crohn's disease (CD) are needed to further explore its efficacy in CD and to better assess its safety profile.
Document type :
Journal articles
Complete list of metadata

https://hal.univ-lorraine.fr/hal-01702865
Contributor : Ngere Ul Connect in order to contact the contributor
Submitted on : Wednesday, February 7, 2018 - 11:48:30 AM
Last modification on : Tuesday, October 13, 2020 - 10:46:37 AM

Identifiers

  • HAL Id : hal-01702865, version 1
  • PUBMED : 23627915

Collections

Citation

Lucine Vuitton, Stéphane Koch, Laurent Peyrin-Biroulet. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.. Current Drug Targets, Bentham Science Publishers, 2013, pp.1385-91. ⟨hal-01702865⟩

Share

Metrics

Record views

97